MedPage Today on MSN
A New Medicare Option for Weight Loss Drugs: What Doctors Should Know
New benefit comes with caveats, particularly around clinical guidelines ...
Can the new GLP-1s help prevent cancer before it starts by tackling obesity and all the dysfunctional metabolic pathways that ...
5don MSN
People who lose weight on Ozempic are viewed worse than people who don’t lose weight at all: study
In the Ozempic era, not all pounds lost are met with praise. New research suggests that people may face more judgment for ...
Despite requiring substantial resources, lifestyle programs are unlikely to be successful without including a strong behavioral change component, one commenter noted.
The rise of new weight-loss drugs could help reframe obesity as a societal failure driven by the food industry, rather than ...
Multiple clinical trials have shown that GLP-1s are safe and effective for patients with obesity, diabetes and cardiovascular ...
New research presented at this year’s European Congress on Obesity (ECO 2026) in Istanbul, Turkey (12-15 May) and published ...
Transforming Healthcare highlights the importance of basic science in solving today's medical challengesJust as every human ...
Weight gain is a common concern for women during menopause, and health care professionals should take a comprehensive ...
Everyday Health on MSN
What to know about Zepbound (tirzepatide), the Mounjaro-like weight loss drug
Compared with rival injectables Wegovy and Ozempic (semaglutide), Zepbound leads to greater weight loss. Learn about how it works, pricing, and side effects.
Bicycling on MSN
Your cycling for weight loss journey goes beyond the numbers. Here’s how to push past plateaus.
It’s so much more than just chasing a number on the scale.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results